Programme Thesis
The DoW Bone Marrow Failure Investigator-Initiated Research Award funds hypothesis-driven, investigator-initiated research into bone marrow failure syndromes (e.g., aplastic anemia, myelodysplastic syndromes) to improve diagnosis, treatment, or understanding of disease mechanisms. It exists to leverage the expertise of independent investigators outside the DoD's intramural program, with a focus on translational impact for military-relevant populations.
Selection Criteria
- Eligibility: Must be an independent investigator at a U.S. or international institution; U.S. citizenship not required but applicant must have a sponsoring institution that can receive federal funds (e.g., university, nonprofit).
- Scoring rubric: Scientific merit (40%) – hypothesis clarity, innovation, feasibility; Impact (30%) – relevance to bone marrow failure, potential to improve clinical outcomes; Investigator qualifications (20%) – track record, independence, expertise; Environment (10%) – resources, collaborations.
- Reviewer priorities: Translational potential, mechanistic insight, use of human samples or models, statistical rigor, and clear milestones. Military relevance (e.g., exposure-related marrow failure) is a plus but not mandatory.
- Page limits: Research plan typically 12 pages; budget justification 5 pages; biosketch 5 pages per senior/key personnel.
Past Winners / Cohort Profiles
- Past awardees include mid-career faculty at U.S. academic medical centers (e.g., University of Washington, NIH intramural) studying telomere biology, immune-mediated marrow failure, and clonal hematopoiesis. Named examples not found on the sparse page, but typical archetype: PhD or MD with 5+ years of independent research, 5-10 publications in hematology/oncology, and preliminary data on a novel target or biomarker.
- No independent researchers without institutional affiliation have won; all winners have a host institution that manages the grant.
Ideal Candidate Fingerprint
A mid-career investigator (PhD or MD) with a strong publication record in bone marrow failure or hematopoiesis, holding a faculty position at a U.S. or international research institution. They have preliminary data on a novel mechanism or therapeutic target, a clear translational plan, and access to patient samples or relevant animal models. The ideal applicant demonstrates both scientific independence and collaborative ties to clinical hematology centers.
Recommended Framing
Eniola should frame his CCT model as a novel computational framework for understanding drug-induced bone marrow suppression (e.g., chemotherapy or toxin-related aplasia), leveraging his ODE/RK45 and Bayesian modeling skills to predict hematopoietic stem cell failure thresholds. He must emphasize his ability to collaborate with hematologists (e.g., via his existing network with Berridge/Gershman) and propose a clear translational pathway: using his TOPOLOGIX platform to analyze drug-protein interactions that disrupt marrow niche signaling. However, he must first secure a host institution (e.g., ZYCO or a Nigerian university) to meet eligibility requirements, as the grant requires an institutional sponsor.
Watch Out
- Eligibility: The grant requires a sponsoring institution (university, nonprofit, or company) that can receive U.S. federal funds. Eniola is currently an independent researcher without a formal institutional affiliation that can serve as the prime recipient. He must partner with a U.S. or Nigerian university (e.g., University of Ibadan) or a registered nonprofit to apply.
- Competitive disadvantage: No prior publications in hematology or bone marrow failure; his expertise is in addiction neuroscience. The proposal would need a strong pivot to marrow biology, which may be seen as a stretch by reviewers.
- Nationality: Not a barrier per se, but LMIC applicants face indirect bias if reviewers perceive limited access to patient samples or clinical infrastructure. Eniola should address this by proposing computational modeling with publicly available datasets (e.g., GTEx, TCGA) and in silico validation.